A new UK-based company, RQ Biotechnology, has emerged from stealth mode via a deal with AstraZeneca to license six early-stage COVID-19 monoclonal antibody candidates worth up to $157m plus royalties.
AstraZeneca already has its antibody combination Evusheld (tixagevimab and cilgavimab) on the market, and the new deal is a sign...








